Hyderabad, Oct 23 (UNI) Dr Reddy's Laboratories Ltd today announced that it has recorded a 30 per cent YoY increase in overall revenues from Rs 12.5 billion during the corresponding period last year to Rs 16.2 billion during the second quarter.
According to a release here, the operating income stood at Rs two billion in second quarter as against Rs 1.1 billion last year, representing a growth of 78 per cent.
EBITDA was reported at Rs 2.7 billion in this quarter as against Rs 2.2 billion the corresponding period previous year, representing a growth of 25 per cent.
PAT recorded a 19 per cent YoY growth from Rs one billion during the corresponding period last year to Rs 1.2 billion this quarter.
Revenues from Global Generics business was reported at Rs 11.2 billion in Q2 FY09 as against Rs eight billion in Q2 FY08. YoY growth of 40 per cent was driven by key markets of North America, Russia and Germany.
Revenues from Pharmaceutical Services and Active Ingredients (PSAI) increased by 10 per cent to Rs 4.8 billion in Q2 FY09 as against Rs 4.4 billion in Q2 FY08. During the quarter, the company launched 35 new generic products, filed 24 new generic product registrations and filed 21 DMFs globally.
UNI VA SJ 1639